Product
Triheptanoin
Aliases
Dojolvi, UX007
Name
DOJOLVI
INN Name
Triheptanoin
FDA Approved
Yes
7 clinical trials
1 organization
15 indications
1 document
Indication
GLUT1 deficiency syndromeIndication
GLUT1DSIndication
EpilepsyIndication
GLUT1 deficiency syndrome 1Indication
autosomal recessiveIndication
Glucose Metabolism DisordersIndication
Glucose Transport DefectIndication
GLUT1 Deficiency SyndromeIndication
Glycogen Storage Disease Type VIIIndication
GYG1 deficiencyClinical trial
Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D)Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase II, Escalating Dose, Open Label Study to Evaluate the Safety of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Triheptanoin's Effect on Fatty Acid Oxidation and Exercise Tolerance in Patients With Debrancher Deficiency, Glycogenin-1 Deficiency and Phosphofructoinase Deficiency at Rest and During Exercise. A Randomized, Double-blind, Placebo-controlled, Cross-over StudyStatus: Completed, Estimated PCD: 2019-08-28
Clinical trial
Compatibility of Triheptanoin (C7) With the Ketogenic Diet in Patients Diagnosed With Glucose Transporter Type 1 DeficiencyStatus: Completed, Estimated PCD: 2021-06-18
Clinical trial
A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared With Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
An Open Label, Exploratory, Proof-of Concept Study of Triheptanoin as Treatment for Patients With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) DeficiencyStatus: Recruiting, Estimated PCD: 2026-12-31
Document
DailyMed Label: DOJOLVIOrganization
Ultragenyx Pharmaceutical Inc.